

Lung Cancer: Small Cell Lung Cancer Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: Neoadjuvant/Pre-Op Adjuvant/Post-Op
 1st Line 2nd Line 3rd Line 3rd Line+ Maintenance

ECOG Performance Status: _____ ICD-10 Code: _____

Biomarkers/Characteristics: (Select all that apply)

ALK Status: Negative Positive Not Reported

MET Amplification: Negative Positive Not Reported

EGFR: Negative Positive Not Reported

RET Gene Rearrangement: Absent Present Not Reported

BRAF: V600E Mutation V600K Mutation

ROS1 Rearrangement: Negative Positive Not Reported

Wild Type Not Reported

Limited Stage | Primary, Adjuvant, or First Line of Therapy (1st Line)

Carboplatin and etoposide ± XRT

Cisplatin and etoposide ± XRT

Extensive Stage | First Line of Therapy (1st Line)

Carboplatin and etoposide

Atezolizumab (Tecentriq), carboplatin, and etoposide

Second and Subsequent Lines of Therapy (2nd Line+) | Relapse Greater than Six (6) Months

Carboplatin and etoposide

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

